FISEVIER

Contents lists available at SciVerse ScienceDirect

# Biochemical and Biophysical Research Communications

journal homepage: www.elsevier.com/locate/ybbrc



# Omega-3 polyunsaturated fatty acid has an anti-oxidant effect via the Nrf-2/HO-1 pathway in 3T3-L1 adipocytes

Chisato Kusunoki <sup>a</sup>, Liu Yang <sup>a</sup>, Takeshi Yoshizaki <sup>a,\*</sup>, Fumiyuki Nakagawa <sup>a</sup>, Atsushi Ishikado <sup>a</sup>, Motoyuki Kondo <sup>a</sup>, Katsutaro Morino <sup>a</sup>, Osamu Sekine <sup>a</sup>, Satoshi Ugi <sup>a</sup>, Yoshihiko Nishio <sup>b</sup>, Atsunori Kashiwagi <sup>a</sup>, Hiroshi Maegawa <sup>a</sup>

### ARTICLE INFO

Article history: Received 25 October 2012 Available online 3 November 2012

Keywords: ω3-Polyunsaturated fatty acid Nrf-2 HO-1 Adipocytes Oxidative stress

#### ABSTRACT

Oxidative stress is produced in adipose tissue of obese subjects and has been associated with obesity-related disorders. Recent studies have shown that omega-3 polyunsaturated fatty acid ( $\omega$ 3-PUFA) has beneficial effects in preventing atherosclerotic diseases and insulin resistance in adipose tissue. However, the role of  $\omega$ 3-PUFA on adipocytes has not been elucidated. In this study, 3T3-L1 adipocytes were treated with  $\omega$ 3-PUFA and its metabolites, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), or 4-hydroxy hexenal (4-HHE).  $\omega$ 3-PUFA and its metabolites dose-dependently increased mRNA and protein levels of the anti-oxidative enzyme, heme oxygenase-1 (HO-1); whereas no changes in the well-known anti-oxidant molecules, superoxide dismutase, catalase, and glutathione peroxidase, were observed. Knockdown of nuclear factor erythroid 2-related factor 2 (Nrf-2) significantly reduced EPA, DHA or 4-HHE-induced HO-1 mRNA and protein expression. Also, pretreatment with  $\omega$ 3-PUFA prevented H<sub>2</sub>O<sub>2</sub>-induced cytotoxicity in a HO-1 dependent manner. In conclusion, treatment with EPA and DHA induced HO-1 through the activation of Nrf-2 and prevented oxidative stress in 3T3-L1 adipocytes. This anti-oxidant defense may be of high therapeutic value for clinical conditions associated with systemic oxidative stress.

© 2012 Elsevier Inc. All rights reserved.

### 1. Introduction

It is well established that obesity increases oxidative stress, which is predictive of vascular disease and associated complications, including vascular dysfunction, insulin resistance, and decreased levels of adiponectin [1–7]. Insulin resistance in adipose tissue leads to systemic insulin resistance in liver and muscle. Therefore, protecting adipocytes against oxidative stress could have clinical value in combating obesity-related metabolic diseases; however, the molecular mechanisms for how oxidative stress is ameliorated in adipocytes have not been fully elucidated.

There is considerable evidence suggesting that omega-3 poly-unsaturated fatty acid ( $\omega$ 3-PUFA), and its metabolites, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have a wide range of biological effects, including anti-inflammatory effects,

E-mail address: yosizaki@belle.shiga-med.ac.jp (T. Yoshizaki).

reduction of cytokine production and decreasing oxidative stress [8]. Recent studies have shown that  $\omega$ 3-PUFA has beneficial effects in the prevention of obesity and insulin resistance, and it has been proposed that ω3-PUFA stimulates muscle glycogen synthesis [9] and improves obesity-induced insulin resistance in the liver [10,11]. It has also been reported that the effects of  $\omega$ 3-PUFA are mediated by the peroxisome proliferator-activated receptors (PPAR)- $\alpha$  dependent pathway in diet-induced obese mice [9–13]. Furthermore,  $\omega$ 3-PUFA has been shown to modulate anti-oxidant enzyme activity, such as superoxide dismutase (SOD) and catalase in livers from diabetic rats fed a high fat diet [14]. There is therefore growing evidence to suggest that ω3-PUFA has an anti-oxidative stress effect, and that the subsequent effects on adipocytes could be of high therapeutic value for obesity-associated disorders. However, the direct mechanistic effect of ω3-PUFA on adipocytes is not yet fully understood.

In the present study, we demonstrate that  $\omega 3$ -PUFA induces the anti-oxidative enzyme, HO-1, through Nrf-2, and show that  $\omega 3$ -PUFA prevented H<sub>2</sub>O<sub>2</sub>-induced cytotoxicity in a HO-1 dependent manner. Our results indicate that  $\omega 3$ -PUFA exerts effects as an anti-oxidant molecule in adipocytes.

<sup>&</sup>lt;sup>a</sup> Department of Medicine, Shiga University of Medical Science, Seta Tsukinowa-Cho, Otsu, Shiga 520-2192, Japan

<sup>&</sup>lt;sup>b</sup> Division of Diabetes, Metabolism and Endocrinology, Department of Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8544. Japan

Abbreviations: ω3-PUFA, ω3-polyunsaturated fatty acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; 4-HHE, 4-hydroxy hexenal; HO-1, heme oxygenase-1; Nrf2, nuclear factor erythroid 2-related factor 2; NQO1, NAD(P)H quinone oxidoreductase 1; ROS, reactive oxygen species; NBT, nitro blue tetrazolium.

<sup>\*</sup> Corresponding author. Fax: +81 77 543 3858.

#### 2. Materials and methods

### 2.1. Reagents

Anti-HO-1, anti-Nrf-2, horseradish peroxidase-linked antimouse and anti-rabbit antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Dulbecco's Modified Eagle's Medium (DMEM), and fetal calf serum (FCS) were obtained from Life Technologies (Grand Island, NY). BioMax MR film was obtained from Eastman Kodak Co. (Rochester, NY). EPA, DHA, 4-HHE, 18-hydroxy-5Z, 8Z, 11Z, 14Z, 16E-eicosapentaenoic acid (18-HEPE), 10(S),17(S)-DiHDoHE, and GW9508 were purchased from Cayman (Ann Arbor, MI). All other reagents and chemicals were from standard suppliers.

# 2.2. Cell cultures

3T3-L1 cells, provided by Dr. J.M. Olefsky (University of California, San Diego, CA), were cultured and differentiated into adipocytes, as previously described [15]. Prior to each experiment, the adipocytes were trypsinized and reseeded in the appropriate culture dishes [16].

# 2.3. Transfection study

The duplexes of siRNA, targeting HO-1, Nrf-2, G-protein coupled receptor (GPR) 120 mRNA, and a negative control were purchased from Santa Cruz Biotechnology. On day 5 post-differentiation, electroporation was performed using Amaxa Nucleofector technology (Amaxa, Cologne, Germany), as previously described [17].

# 2.4. Western blotting

Total protein samples were prepared, as previously described [17], and were resolved by sodium dodecyl sulfate–polyacrylamide gel electrophoresis before being transferred to membranes. Membranes were probed with antibodies against HO-1, and  $\beta$ -actin.

# 2.5. RNA preparation from adipocytes and quantitative RT-PCR

Total RNA samples were prepared and reverse transcription (RT)-PCR reactions were performed, as previously described [18]. Gene expression levels were calculated after normalization to the standard housekeeping genes, GAPDH, using the delta/delta Ct methods, as previously described [19], and expressed as relative mRNA levels when compared with the internal control. Primer sets were as follows: mouse HO-1, 5'-CGAAACAAGCAGAACCCAGTCT-3' and 5'-AGCCCTTCGGTGCAGCT-3'; mouse catalase, 5'-ACA-AGAAAGAAACCTGATGGAGAGA-3' and 5'-GCCAGAAGAGAAACCCA-CAGA-3'; mouse MnSOD, 5'-CTTCAATAAGGAGCAAGGTCGC-3' and 5'-CACACGTCAATCCCCAGC-3'; mouse CuZnSOD, 5'-AATGGTGGTC-CATGAGAAACAAG-3' and 5'-GCAATCCCAATCACTCCACA-3'; mouse Nqo1, 5'-GTCTTCTCTGAATGGGCCAG-3' and 5'-TTTAGGGTCGTC TTGGCAAC-3'; mouse Gpx, 5'-GGGCAAGGTGCTCATTG-3' and 5'-AGAGCGGGTGAGCCTTCTCA-3'; mouse Nrf-2, 5'-GGTTCAGT-GACTCGGAAATGG-3' and 5'-GAGAATGTGCTGGCTGTGCT-3' and mouse GPR120, 5'-ACCAAGTCAATCGCACCCACTTCCC-3' and 5'-GGTCTCCACGACGCTCAACACCAAC-3' and mouse GAPDH, 5'-GCCTGCTTCACCACCTTCT-3' and 5'-ATGGCCTTCCGTGTTCCT-3'.

# 2.6. NBT assay

Reactive oxygen species (ROS) production was detected by nitroblue tetrazolium (NBT) assay [20]. 3T3-L1 adipocytes were incubated with  $100~\mu M$  of BSA, EPA or DHA for 1~h pretreated with

or without N-acetyl-L-cysteine (NAC). Cells were stimulated with or without  $H_2O_2$  for 24 h and then incubated for 90 min in PBS containing 0.2% NBT. NBT is reduced by ROS to a dark-blue insoluble form of NBT called formazan. Formazan was dissolved in 50% acetic acid and the absorbance was determined at 560 nm.

# 2.7. Statistical analysis

All values are expressed as mean  $\pm$  SEM unless otherwise stated. Scheffe's multiple comparison test was used to determine the significance of any differences between more than three groups. A p value less than 0.05 was considered significant.

#### 3. Results

3.1. EPA and DHA induced anti-oxidative enzyme HO-1 and NQO1 in 3T3-L1 adipocytes

Since  $\omega 3$ -PUFA is considered an anti-oxidant molecule in aortic cells [21], we evaluated whether it also has an anti-oxidative effect on adipocytes. Unexpectedly, treatment with EPA and DHA in 3T3-L1 adipocytes had no effect on the expression of manganese superoxide dismutase (MnSOD), copper/zinc SOD (Cu/ZnSOD), catalase or glutathione peroxidase (GPx) mRNA expression (Fig. 1A–D). However, treatment with each reagent for 8 h increased the anti-oxidant enzyme, HO-1, and NAD(P)H quinone oxidoreductase 1 (NQO1) mRNA expression (Fig. 1E and F). Additionally, HO-1 mRNA expression by EPA and DHA was in a dose-dependent manner (Fig. 1G). We found that each reagent caused a maximal increase in HO-1 mRNA expression for 8 h (Fig. 1G). Furthermore, treatment with EPA and DHA for 24 h increased the intracellular protein expression of HO-1 (Fig. 1H).

## 3.2. 4-HHE induced HO-1 mRNA in 3T3-L1 adipocytes

ω3-PUFA is considered to be metabolized to its metabolites, and these metabolites exhibit beneficial effects. 18-HEPE is produced by non-enzymatic oxidation of EPA, and 10(S),17(S)-DiHDoHE, also referred to as protectin D1, is a DHA metabolite. As they have been reported to be representative members of DHA- and EPA-derived lipid mediators and mimic beneficial actions as potent protective, anti-inflammatory, and pro-resolution properties [10,11], we examined whether 18-HEPE and 10(S),17(S)-DiHDoHE increased HO-1 mRNA expression and found neither induced HO-1 in 3T3-L1 adipocytes (Fig. 2A).

We then examined the effect of another end-product aldehyde of  $\omega 3$ -PUFA peroxidation, 4-HHE. Interestingly, 4-HHE induced HO-1 mRNA expression (Fig. 2A). 4-HHE caused a maximal increase in HO-1 mRNA expression after 6 h (Fig. 2B). Treatment with 4-HHE dose-dependently increased HO-1 mRNA expression (Fig. 2C).

As it has been reported that DHA leads to an increase in glucose uptake via GPR120 in 3T3-L1 adipocytes [22], we stimulated GPR120 with synthetic agonists, GW9508, to examine whether GPR senses the anti-oxidant enzyme, HO-1. Our results showed that GW9508 did not induce HO-1 mRNA expression (Fig. 2D).

# 3.3. EPA, DHA and 4-HHE induced HO-1 expression through Nrf-2 in 3T3-L1 adipocytes

The findings presented in Fig. 2 suggest that  $\omega$ 3-PUFA induced HO-1 expression, not through the GPR120 pathway. To explore which pathways are critical for the induction of HO-1 by  $\omega$ 3-PUFA, we transfected 3T3-L1 adipocytes with siRNA against Nrf-2, a






Fig. 1. Treatment with EPA and DHA induced the antioxidative enzyme HO-1 and NQ01 in 3T3-L1 adipocytes. 3T3-L1 adipocytes were pretreated with the concentration indicated (G) or 100  $\mu$ M (A–G) BSA, EPA or DHA for the indicated time (G), or 8 h (A–G). Total RNA was purified and quantitative RT-PCR was performed. Data are presented as the relative expression and normalized to GAPDH. (H) 3T3-L1 adipocytes were stimulated with 100  $\mu$ M BSA, EPA or DHA, and lysed and immunoblotting (IB) was performed with indicated antibodies. The graph show the mean  $\pm$  S.E. and the values are expressed as fold increase compared to control.  $\beta$ -actin was showed as an endogenous control.  $\gamma$ 0.01, \*\* $\rho$ 0.05, compared with control. NS, no significant difference.



**Fig. 2.** 4-HHE induced HO-1 mRNA in 3T3-L1 adipocytes. The 3T3-L1 adipocytes were stimulated with concentration indicated (C) or 50 μM 4HHE, 50 nM 18-HEPE, 50 nM 10(S),17(S)-DiHDoHE, and 20 μM GW9508 for the indicated time (B) or 6 h (A, D). Total RNA was purified and quantitative RT-PCR was performed. Data are presented as the relative expression and normalized to GAPDH. Error bars represent the mean ± S.E. \*P < 0.01, compared with control. NS, no significant difference.

well-known upstream regulator of HO-1, and GPR120, by electroporation. Twenty-four hours after electroporation, we observed a 70% and 60% decrease in both Nrf-2 and GPR120 mRNA in cells transfected with siRNA against Nrf-2 (Fig. 3A) or GPR120 (Fig. 3D), respectively, when compared with cells transfected with control siRNA. Depletion of Nrf-2 abolished EPA or DHA induced

HO-1 expression (Fig. 3A and B). 4HHE also had no effect on HO-1 expression in Nrf-2 knock down cells (Fig. 3C). However, depletion of GPR120 had no effect on  $\omega 3$ -PUFA induced HO-1 expression (Fig. 3D). These findings indicate that  $\omega 3$ -PUFA increased the expression of HO-1 through the Nrf-2 pathway, but not through the GPR120 pathway.



**Fig. 3.** EPA, DHA and 4-HHE induced HO-1 expression through Nrf-2 in 3T3-L1 adipocytes. (A–C) 3T3-L1 adipocytes were electroporated with siRNA against Nrf-2 or control siRNA for 24 h. After electroporation, treatment of 100 μM BSA, EPA, DHA (A, B), or 50 μM 4-HHE (C), and then HO-1 mRNA (A, C) or protein (B) was evaluated by quantitative RT-PCR or Western blotting. (D) 3T3-L1 adipocytes electroporated with siRNA against GPR120 or control siRNA, were stimulated with 100 μM BSA, EPA or DHA. Total RNA was extracted and the relative mRNA expression of HO-1 and GPR120 was analyzed by RT-PCR. Results were normalized to GAPDH and expressed as fold increase over BSA-treated control siRNA electroporated cells. Values are expressed as the means  $\pm$  S.E.  $^*P$  < 0.05, compared with control. N.S., no significant difference.

# 3.4. EPA and DHA protects against $H_2O_2$ -induced ROS production in 3T3-L1 adipocytes

To evaluate the physiological role of  $\omega 3$ -PUFA induced HO-1 expression, we assessed the cytoprotective effects of EPA and DHA against H<sub>2</sub>O<sub>2</sub>-induced oxidative stress. We examined cell viability, assessed using a NBT assay, after the induction of oxidative stress by H<sub>2</sub>O<sub>2</sub> for 24 h and found that EPA and DHA partially prevented H<sub>2</sub>O<sub>2</sub>-induced ROS production, compared with BSA alone (Fig. 4A). Administration of NAC attenuated H<sub>2</sub>O<sub>2</sub>-induced NBT reduction, but EPA and DHA had no additive effect, suggesting that  $\omega 3$ -PUFA exerts effects as an anti-oxidant molecule and prevented H<sub>2</sub>O<sub>2</sub>-induced ROS production.

To further confirm the role of HO-1 on  $\omega 3$ -PUFA's protective effect from  $H_2O_2$ -induced ROS production, we performed a NBT assay in HO-1 knockdown cells. Transfection with HO-1 siRNA reduced the expression of HO-1 mRNA by close to 80% (Fig. 4B). As shown in Fig. 4C, attenuation of ROS production by EPA and DHA was significantly suppressed in these cells, suggesting that  $\omega 3$ -PUFA attenuates ROS production through HO-1 induction.


## 4. Discussion

In this study, we show a novel direct anti-oxidant role of  $\omega$ 3-PUFA on adipocytes.  $\omega$ 3-PUFA is able to increase HO-1 expression

through the activation of Nrf-2 in 3T3-L1 adipocytes. We also reveal a preventive effect of  $\omega$ 3-PUFA against H<sub>2</sub>O<sub>2</sub>-induced ROS production.

Chronic low-grade adipose tissue inflammation is a major cause of systemic insulin resistance that exists in obesity-related disorders such as type 2 diabetes. Although the roles of tissue macrophages and adipocytes in this process have been well documented, recent studies have focused on the direct effect of ω3-PUFA within a macrophage. For example, one study has reported that a biological mechanism responsible for the anti-inflammatory effects of ω3-PUFA is by way of GPR120 in macrophages [22]; and in another, it was reported that EPA increases adiponectin levels and improves insulin sensitivity through the inhibition of inflammatory responses in macrophage in vivo [23]. These reports suggest that ω3-PUFA affects adipose tissue macrophages. However, the direct effect of ω3-PUFA on the adipocytes themselves has not been elucidated. In this regard, in 3T3-L1 adipocytes, we show, for the first time, that ω3-PUFA leads to an increase in expression of HO-1 via the Nrf-2 pathway and inhibits H<sub>2</sub>O<sub>2</sub>-induced ROS generation. Results demonstrate that ω3-PUFA exerts effects as an anti-oxidant and cytoprotective component within adipocytes.

To elucidate the molecular mechanism producing the anti-oxidant role of  $\omega$ 3-PUFA on adipocytes, we examined anti-oxidant enzymes. We showed that treatment with EPA and DHA in 3T3-L1 adipocytes increased HO-1 and NQO1 mRNA expression; however,



**Fig. 4.** Preventive effects of EPA and DHA on  $H_2O_2$ -induced cytotoxicity in 3T3-L1 adipocytes. (A) 3T3-L1 adipocytes pretreated with or without 10 mM NAC for 1 h, were treated with 100 μM BSA, EPA, or DHA for 1 h, and then stimulated with 500 μM  $H_2O_2$  for 24 h. (B) 3T3-L1 adipocytes were electroporated with control siRNA or HO-1 siRNA. Cells pretreated with 100 μM BSA, EPA, or DHA were stimulated with 500 μM  $H_2O_2$  for 24 h. Total RNA was purified and quantitative RT-PCR performed. Data are presented at the relative expression and normalized to GAPDH. ROS production was measured by NBT assay as described Section 2. Values represent the means ± S.E. of four experiments, compared with BSA-treated  $H_2O_2$ -untreated HO-1 knockdown cells. \* $^P$  < 0.01, compared with BSA treated  $^{*P}$  < 0.01, compared with BSA treated  $^{*P}$  < 0.01, compared with BSA treated  $^{*P}$  < 0.01, significant difference.

they had no effect on the expression of MnSOD, Cu/ZnSOD, catalase and GPx mRNA expression.  $\omega$ 3-PUFA is known as one of the PPARs activators [24], and PPARs ligands may activate anti-oxidant enzymes such as SOD and catalase in the liver and skeletal muscle [25–27]. Our results indicate that  $\omega$ 3-PUFA may have an anti-oxidant role through a distinct mechanism in adipocytes.

We also observed that there were differences in the impact of EPA and DHA on the anti-oxidative effects. DHA significantly increased HO-1 mRNA and protein levels more than EPA, and it also had a protective effect from H<sub>2</sub>O<sub>2</sub>-induced ROS production. In the context of anti-inflammation, it has been reported that DHA may also be more effective than EPA in alleviating LPS-induced proinflammatory cytokine production in macrophages [28], although there is evidence to suggest that  $\omega$ 3-PUFA can mediate the activity of transcription factors, such as NF-κB [29,30]. We considered that the differences observed between EPA and DHA might result from differences in the metabolism of each reagent. 4-HHE, which is metabolized from ω3-PUFA, was able to increase HO-1 expression through Nrf-2 activation earlier than from EPA and DHA (6 vs. 8 h). The time needed to metabolize to 4-HHE from EPA or DHA might cause this time lag. Also, we found that DHA, more so than EPA, causes an increase in intracellular 4-HHE (unpublished data). Further investigation into how EPA or DHA metabolizes to 4-HHE, and how 4-HHE activates Nrf-2, may solve this issue.

Although  $\omega$ 3-PUFA has been reported to increase glucose uptake via GPR120 in 3T3-L1 adipocytes [22], in the current study, we observed that EPA and DHA had an anti-oxidant effect through the Nrf-2/HO-1 pathway. This observation, together with a recent study showing that 4-HHE, a peroxidation product of  $\omega$ 3-PUFA, is able to stimulate HO-1 expression through the activation of Nrf-2 and has a preventive effect against oxidative stress-induced cyto-

toxicity in vascular endothelial cells [31], leads us to believe that our data demonstrate that  $\omega$ 3-PUFA exerts effects as an anti-oxidant and cytoprotective component in adipocytes. Furthermore, depletion of HO-1 increased basal (lane 1 vs. lane 7) and H<sub>2</sub>O<sub>2</sub>-induced (lane 4 vs. lane 10) ROS production (Fig. 4C), suggesting that HO-1 is involved with the anti-oxidant effects seen in adipocytes.

Although the role of the Nrf-2/HO-1 pathway is still being considered, HO-1 is a well-known molecular response to oxidative stress, and it is becoming increasingly clear that appropriate low levels of oxidative stress protect against upcoming severe oxidative stress. This is an area of current interest, called preconditioning. In this regard,  $\omega 3$ -PUFA increased HO-1 protein expression by 1.5- to 2.5-fold (Fig. 1H) and protected against  $\rm H_2O_2$ -induced ROS production (Fig. 4A). The levels of HO-1 induction observed in our study might be an appropriate level of expression to prevent oxidative stress. In ischemic heart disease, preconditioning has been well established. However, the potential of preconditioning procedures to oxidative stress in adipocytes requires investigation.

It has been suggested that fish, or fish-oil, as a dietary supplement may reduce the risk of cardiovascular disease, lower blood pressure, and modify lipid metabolism and inflammation [32,33]. These beneficial effects might be through HO-induction and antioxidant effects in adipocytes. Further *in vivo* study is needed, but it is of interest that there is an improvement shown in adipocytes to the effects of oxidative stress by dietary supplementation of  $\omega$ 3-PUFA. It is also of interest that the reduction of oxidative stress attenuates obesity-related systemic insulin resistance.

In summary, we show, for the first time, that  $\omega 3$ -PUFA has an anti-oxidative stress effect through expression of HO-1 via the Nrf-2 pathway in 3T3-L1 adipocytes. In a broader context, our findings strongly suggest that an enhancement of the anti-oxidant

defense has high therapeutic value, and HO-1 should be one of the therapeutic approaches because of its dynamically modulatory properties.

### Acknowledgments

We thank Jerrold M. Olefsky (University of California, San Diego, CA) for providing 3T3-L1 adipocytes. We are grateful to Takeshi Imamura and Yoshio Nagai for their scientific input and contributions. We also thank Ms. Keiko Kosaka and Megumi Matsuo for their technical assistance. This work was supported in part by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology, Japan (to T.Y., S.U. and H.M.).

#### References

- [1] J.E. Hall, The kidney, hypertension, and obesity, Hypertension 41 (2003) 625–633.
- [2] M. Li, D.H. Kim, P.L. Tsenovoy, S.J. Peterson, R. Rezzani, L.F. Rodella, W.S. Aronow, S. Ikehara, N.G. Abraham, Treatment of obese diabetic mice with a heme oxygenase inducer reduces visceral and subcutaneous adiposity, increases adiponectin levels, and improves insulin sensitivity and glucose tolerance, Diabetes 57 (2008) 1526–1535.
- [3] C. Kobashi, M. Urakaze, M. Kishida, E. Kibayashi, H. Kobayashi, S. Kihara, T. Funahashi, M. Takata, R. Temaru, A. Sato, K. Yamazaki, N. Nakamura, M. Kobayashi, Adiponectin inhibits endothelial synthesis of interleukin-8, Circ. Res. 97 (2005) 1245–1252.
- [4] K.E. Wellen, G.S. Hotamisligil, Obesity-induced inflammatory changes in adipose tissue, J. Clin. Invest. 112 (2003) 1785–1788.
- [5] B.E. Wisse, The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity, J. Am. Soc. Nephrol. 15 (2004) 2792– 2800
- [6] A.D. Dobrian, M.J. Davies, S.D. Schriver, T.J. Lauterio, R.L. Prewitt, Oxidative stress in a rat model of obesity-induced hypertension, Hypertension 37 (2001) 554–560.
- [7] S. Furukawa, T. Fujita, M. Shimabukuro, M. Iwaki, Y. Yamada, Y. Nakajima, O. Nakayama, M. Makishima, M. Matsuda, I. Shimomura, Increased oxidative stress in obesity and its impact on metabolic syndrome, J. Clin. Invest. 114 (2004) 1752–1761.
- [8] T.A. Mori, R.J. Woodman, V. Burke, I.B. Puddey, K.D. Croft, L.J. Beilin, Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects, Free Radical Biol. Med. 35 (2003) 772–781.
- [9] O. Kuda, T. Jelenik, Z. Jilkova, P. Flachs, M. Rossmeisl, M. Hensler, L. Kazdova, N. Ogston, M. Baranowski, J. Gorski, P. Janovska, V. Kus, J. Polak, V. Mohamed-Ali, R. Burcelin, S. Cinti, M. Bryhn, J. Kopecky, N-3 fatty acids and rosiglitazone improve insulin sensitivity through additive stimulatory effects on muscle glycogen synthesis in mice fed a high-fat diet, Diabetologia 52 (2009) 941–951.
- [10] C.N. Serhan, S. Hong, K. Gronert, S.P. Colgan, P.R. Devchand, G. Mirick, R.L. Moussignac, Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals, J. Exp. Med. 196 (2002) 1025–1037.
- [11] A. Gonzalez-Periz, R. Horrillo, N. Ferre, K. Gronert, B. Dong, E. Moran-Salvador, E. Titos, M. Martinez-Clemente, M. Lopez-Parra, V. Arroyo, J. Claria, Obesityinduced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins, FASEB J. 23 (2009) 1946–1957.
- [12] L.M. Sanderson, P.J. de Groot, G.J. Hooiveld, A. Koppen, E. Kalkhoven, M. Muller, S. Kersten, Effect of synthetic dietary triglycerides: a novel research paradigm for nutrigenomics, PLoS ONE 3 (2008) e1681.
- [13] M. Wakutsu, N. Tsunoda, S. Shiba, E. Muraki, K. Kasono, Peroxisome proliferator-activated receptors (PPARs)-independent functions of fish oil on glucose and lipid metabolism in diet-induced obese mice, Lipids Health Dis. 9 (2010) 101.
- [14] A.M. de Assis, A. Rech, A. Longoni, L.N. Rotta, C.C. Denardin, M.A. Pasquali, D.O. Souza, M.L. Perry, J.C. Moreira, Omega3-Polyunsaturated fatty acids prevent lipoperoxidation, modulate antioxidant enzymes, and reduce lipid content but

- do not alter glycogen metabolism in the livers of diabetic rats fed on a high fat thermolyzed diet, Mol. Cell. Biochem. 361 (2012) 151–160.
- [15] S. Ugi, T. Imamura, H. Maegawa, K. Egawa, T. Yoshizaki, K. Shi, T. Obata, Y. Ebina, A. Kashiwagi, J.M. Olefsky, Protein phosphatase 2A negatively regulates insulin's metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3T3-L1 adipocytes, Mol. Cell. Biol. 24 (2004) 8778–8789.
- [16] T. Yoshizaki, H. Maegawa, K. Egawa, S. Ugi, Y. Nishio, T. Imamura, T. Kobayashi, S. Tamura, J.M. Olefsky, A. Kashiwagi, Protein phosphatase-2C alpha as a positive regulator of insulin sensitivity through direct activation of phosphatidylinositol 3-kinase in 3T3-L1 adipocytes, J. Biol. Chem. 279 (2004) 22715–22726.
- [17] Y. Tao, H. Maegawa, S. Ugi, K. Ikeda, Y. Nagai, K. Egawa, T. Nakamura, S. Tsukada, Y. Nishio, S. Maeda, A. Kashiwagi, The transcription factor AP-2beta causes cell enlargement and insulin resistance in 3T3-L1 adipocytes, Endocrinology 147 (2006) 1685–1696.
- [18] T. Yoshizaki, S. Schenk, T. Imamura, J.L. Babendure, N. Sonoda, E.J. Bae, D.Y. Oh, M. Lu, J.C. Milne, C. Westphal, G. Bandyopadhyay, J.M. Olefsky, SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity, Am. J. Physiol. Endocrinol. Metab. 298 (2010) E419–E428.
- [19] T. Yoshizaki, C. Kusunoki, M. Kondo, M. Yasuda, S. Kume, K. Morino, O. Sekine, S. Ugi, T. Uzu, Y. Nishio, A. Kashiwagi, H. Maegawa, Autophagy regulates inflammation in adipocytes, Biochem. Biophys. Res. Commun. 417 (2012) 352– 357
- [20] H.R. Oliveira, R. Verlengia, C.R. Carvalho, L.R. Britto, R. Curi, A.R. Carpinelli, Pancreatic beta-cells express phagocyte-like NAD(P)H oxidase, Diabetes 52 (2003) 1457–1463.
- [21] D. Richard, K. Kefi, U. Barbe, P. Bausero, F. Visioli, Polyunsaturated fatty acids as antioxidants, Pharmacol. Res. 57 (2008) 451–455.
- [22] D.Y. Oh, S. Talukdar, E.J. Bae, T. Imamura, H. Morinaga, W. Fan, P. Li, W.J. Lu, S.M. Watkins, J.M. Olefsky, GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects, Cell 142 (2010) 687-698.
- [23] M. Itoh, T. Suganami, N. Satoh, K. Tanimoto-Koyama, X. Yuan, M. Tanaka, H. Kawano, T. Yano, S. Aoe, M. Takeya, A. Shimatsu, H. Kuzuya, Y. Kamei, Y. Ogawa, Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects, Arterioscler. Thromb. Vasc. Biol. 27 (2007) 1918–1925.
- [24] Q. Lin, S.E. Ruuska, N.S. Shaw, D. Dong, N. Noy, Ligand selectivity of the peroxisome proliferator-activated receptor alpha, Biochemistry 38 (1999) 185–190
- [25] T. Toyama, H. Nakamura, Y. Harano, N. Yamauchi, A. Morita, T. Kirishima, M. Minami, Y. Itoh, T. Okanoue, PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats, Biochem. Biophys. Res. Commun. 324 (2004) 697–704
- [26] J. Berger, D.E. Moller, The mechanisms of action of PPARs, Annu. Rev. Med. 53 (2002) 409-435.
- [27] L.L. Ji, Modulation of skeletal muscle antioxidant defense by exercise: role of redox signaling, Free Radical Biol Med 44 (2008) 142–152.
- [28] S.M. Weldon, A.C. Mullen, C.E. Loscher, L.A. Hurley, H.M. Roche, Docosahexaenoic acid induces an anti-inflammatory profile in lipopolysaccharide-stimulated human THP-1 macrophages more effectively than eicosapentaenoic acid, J. Nutr. Biochem. 18 (2007) 250–258.
- [29] W. Komatsu, K. Ishihara, M. Murata, H. Saito, K. Shinohara, Docosahexaenoic acid suppresses nitric oxide production and inducible nitric oxide synthase expression in interferon-gamma plus lipopolysaccharide-stimulated murine macrophages by inhibiting the oxidative stress, Free Radical Biol Med 34 (2003) 1006–1016.
- [30] Y. Zhao, S. Joshi-Barve, S. Barve, L.H. Chen, Eicosapentaenoic acid prevents LPS-induced TNF-alpha expression by preventing NF-kappaB activation, J. Am. Coll. Nutr. 23 (2004) 71–78.
- [31] A. Ishikado, Y. Nishio, K. Morino, S. Ugi, H. Kondo, T. Makino, A. Kashiwagi, H. Maegawa, Low concentration of 4-hydroxy hexenal increases heme oxygenase-1 expression through activation of Nrf2 and antioxidative activity in vascular endothelial cells, Biochem. Biophys. Res. Commun. 402 (2010) 99-104.
- [32] E.C. Rizos, E.E. Ntzani, E. Bika, M.S. Kostapanos, M.S. Elisaf, Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis, JAMA 308 (2012) 1024–1033.
- [33] S.M. Prescott, W.F. Stenson, Fish oil fix, Nat. Med. 11 (2005) 596-598.